Modulation of Telomerase Promoter Tumor Selectivity in the Context of Oncolytic Adenoviruses
- 1 February 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (3) , 1299-1307
- https://doi.org/10.1158/0008-5472.can-06-3000
Abstract
The telomerase RNA (hTR) and reverse transcriptase (hTERT) promoters are active in most cancer cells, but not in normal cells, and are useful for transcriptional targeting in gene therapy models. Telomerase-specific conditionally replicating adenoviruses (CRAd) are attractive vectors because they should selectively lyse tumor cells. Here, we compare CRAds, in which either the hTR or hTERT promoter controls expression of the adenovirus E1A gene. In replication-defective reporter adenoviruses, the hTR promoter was up to 57-fold stronger in cancer cells than normal cells and up to 49-fold stronger than hTERT. In normal cells, hTERT promoter activity was essentially absent. Doses of telomerase-specific CRAds between 1.8 and 28 infectious units per cell efficiently killed cancer cells, but normal cells required higher doses. However, CRAd DNA replication and E1A expression were detected in both cancer and normal cells. Overall, tumor specificity of the CRAds was limited compared with nonreplicating vectors. Surprisingly, both CRAds expressed similar E1A levels and functional behavior, despite known differentials between hTR and hTERT promoter activities, suggesting that the promoters are deregulated. Rapid amplification of cDNA ends analysis of hTR-/hTERT-E1A transcripts ruled out cryptic transcription from the vector backbone. Blocking E1A translation partially restored the hTR-/hTERT-E1A mRNA differential, evidencing feedback regulation by E1A. [Cancer Res 2007;67(3):1299–307]Keywords
This publication has 42 references indexed in Scilit:
- Noninvasive Imaging of the Transcriptional Activities of Human Telomerase Promoter Fragments in MiceCancer Research, 2004
- Ad-mTERT-Δ19, a Conditional Replication-Competent Adenovirus Driven by the Human Telomerase Promoter, Selectively Replicates in and Elicits Cytopathic Effect in a Cancer Cell-Specific MannerHuman Gene Therapy, 2003
- Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductaseOncogene, 2003
- A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivoOncogene, 2002
- Telomerase and cancer: time to move from a promising target to a clinical realityThe Journal of Pathology, 2001
- Telomerase: a therapeutic target for the third millennium?Critical Reviews in Oncology/Hematology, 2000
- The Use of Laser Scanning Cytometry to Assess Depth of Penetration of Adenovirus p53 Gene Therapy in Human Xenograft BiopsiesThe American Journal of Pathology, 1999
- Is small cell lung cancer the perfect target for anti-telomerase treatment?Carcinogenesis: Integrative Cancer Research, 1999
- Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridizationOncogene, 1998
- A survey of telomerase activity in human cancerPublished by Elsevier ,1997